SEARCH · PubMed Health

Results for “statement”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 559 records · Page 31Linked to original sources

PubMed1991

Alcohol and hypertension--implications for management. A consensus statement by the World Hypertension League.

The World Hypertension League (WHL) is an association of antihypertensive leagues, hypertension societies, committees and other national bodies whose aim is to control hypertension in populations. The present paper is the fourth in a series of 'In the Focus Statements' on topics selected for their practical importance to the management of hypertension, addressed to practising physicians. Like the earlier papers, it has been repeatedly and extensively discussed by the representatives of WHL's member organizations' and accepted as a consensus document.

Alcohol Drinking↗

PubMed1995

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American Heart Association, and the European Resuscitation Council.

This consensus document is an attempt to provide an organized method of reporting pediatric ALS data in out-of-hospital, emergency department, and in-hospital settings. For this methodology to gain wide acceptance, the task force encourages development of a common data set for both adult and pediatric ALS interventions. In addition, every effort should be made to ensure that consistent definitions are used in all age groups. As health care changes, we will all be challenged to document the effectiveness of what we currently do and show how new interventions or methods of treatment improve outcome and/or reduce cost. Only through collaborative research will we obtain the necessary data. For these reasons, and to improve the quality of care and patient outcomes, it is the hope of the task force that clinical researchers will follow the recommendations in this document. It is recognized that further refinements of this statement will be needed; these recommendations will improve only when researchers, clinicians, and EMS personnel use them, work with them, and modify them. Suggestions, emendations, and other comments aimed at improving the reporting of pediatric resuscitation should be sent to Arno Zaritsky, MD, Eastern Virginia Medical School, Children's Hospital of The King's Daughter, Division of Critical Care Medicine, 601 Children's Lane, Norfolk, VA 23507.

Child↗

PubMed1995

The American Heart Association Consensus Statement on guidelines for carotid endarterectomy.

The process by which a multidisciplinary, expert panel arrived at a Consensus Statement concerning indications for carotid endarterectomy was reviewed. It is important to point out that this represents an interpretation of currently available data by the individual members of the Committee as it pertains to 96 specific potential indications for carotid endarterectomy. Clearly, as more data become available, it is likely that there will be changes in the opinion of the Committee members. Therefore, this represents a current status that will require a periodic update.

American Heart Association↗

PubMed1993

European consensus statement on the prevention of venous thromboembolism. European Consensus Conference, Windsor, U.K., November, 1991.

Since the Consensus Conference of the National Institute of Health in 1986, the developments in the field of prevention of venous thromboembolism were mainly characterized by a more specific and extended use of new prophylactic agents such as low molecular weight heparins as well as the perception that outpatients may be at risk for thromboembolic complications, too. Therefore, in November 1991, a European Consensus Conference on the prevention of thromboembolism was held in Windsor, UK, in order to analyse the risk constellation of various patient populations and to give recommendations for primary prophylaxis in general surgery, urology, neurosurgery, orthopaedic and trauma surgery, obstetrics and gynaecology and medical patients. In addition, the cost-effectiveness of the various methods was highlighted, and the question of secondary prevention addressed. The meeting was organized under the patronage of the European Economic Commission, and experts from 15 different countries were invited to participate. The conference was organized according to acknowledged guidelines of consensus conference organization, i.e. each expert had to formulate his provisional standpoint, the working documents were compiled by the organizer, and this file was sent to the delegates before the conference. During the first part of the meeting, the delegates presented their views in plenary sessions. Controversial points were discussed in working groups, and the results were discussed in plenary sessions. Consensus or lack of accord was documented and the open questions were formulated in order to be answered by future studies. The published statements and recommendations are based on different levels of evidence.(ABSTRACT TRUNCATED AT 250 WORDS)

Clinical Trials as Topic↗

PubMed1993

[Revision of consensus statement on imaging diagnosis of the breast].

Changes which have taken place since 1983, when the Dutch consensus meeting on mammography was held, made it necessary to review the consensus statement. In 1983 only radiologists participated in the working group, in 1993 representatives from all other relevant disciplines participated as well. Much attention was paid to the indication for mammography and supplementary diagnostic methods, especially ultrasound techniques and US-guided cytology. Along the lines given by the ACR guidelines on breast cancer reporting, attention was given to better communication with referring doctors.

Biopsy, Needle↗

PubMed1996

Psychiatry of the elderly. Consensus statement: WHO and the Geriatric Psychiatry Section of the World Psychiatric Association.

J. Wertheimer, Professor for psychogeriatrics at the University of Lausanne and Chairman, Geriatric Psychiatry Section, World Psychiatric Association (WPA) and Dr. J. A. Costa e Silva, Director, Division of Mental Health and Prevention of Substance Abuse (WHO) organized a Consensus Meeting which took place in Lausanne from 05.-07.02.1996. The meeting aimed at the elaboration of recommendations on psychogeriatrics. The meeting was attended by the above mentioned WHO and WPA representatives and also by representatives from the following organisations: International Psychogeriatric Association, International Association of Gerontology, International Union of Psychological Science, Alzheimer's Disease International, International Council of Nurses, International Federation of Social Workers, International Federation of Ageing, World Federation of Occupational Therapists. Further attendants were various experts who participated at the meeting on invitation of Prof. Wertheimer and Dr. Costa e Silva. The discussion was chaired by Prof. H. Häfner (Mannheim). Dr. N. Graham (London) and Prof. C. Katona (Harlow/Essex) acted as co-rapporteurs. The Consensus Statement was unamnimously accepted by all participants. It contains recommendations for the development within a field of great future importance with regard to the current and expected global demographic structure and the increasing knowledge about agespecific diseases and general health, social and personal problems of the elderly.

Aged↗

PubMedDate not supplied

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression.

OBJECTIVE: A consensus conference on the reasons for the undertreatment of depression was organized by the National Depressive and Manic Depressive Association (NDMDA) on January 17-18, 1996. The target audience included health policymakers, clinicians, patients and their families, and the public at large. Six key questions were addressed: (1) Is depression undertreated in the community and in the clinic? (2) What is the economic cost to society of depression? (3) What have been the efforts in the past to redress undertreatment and how successful have they been? (4) What are the reasons for the gap between our knowledge of the diagnosis and treatment of depression and actual treatment received in this country? (5) What can we do to narrow this gap? (6) What can we do immediately to narrow this gap? PARTICIPANTS: Consensus panel members were drawn from psychiatry, psychology, family practice, internal medicine, managed care and public health, consumers, and the general public. The panelists listened to a set of presentations with background papers from experts on diagnosis, epidemiology, treatment, and cost of treatment. EVIDENCE: Experts summarized relevant data from the world scientific literature on the 6 questions posed for the conference. CONSENSUS PROCESS: Panel members discussed openly all material presented to them in executive session. Selected panelists prepared first drafts of the consensus statements for each question. All of these drafts were read by all panelists and were edited and reedited until consensus was achieved. CONCLUSIONS: There is overwhelming evidence that individuals with depression are being seriously undertreated. Safe, effective, and economical treatments are available. The cost to individuals and society of this undertreatment is substantial. Long suffering, suicide, occupational impairment, and impairment in interpersonal and family relationships exist. Efforts to redress this gap have included provider educational programs and public educational programs. Reasons for the continuing gap include patient, provider, and health care system factors. Patient-based reasons include failure to recognize the symptoms, underestimating the severity, limited access, reluctance to see a mental health care specialist due to stigma, noncompliance with treatment, and lack of health insurance. Provider factors include poor professional school education about depression, limited training in interpersonal skills, stigma, inadequate time to evaluate and treat depression, failure to consider psychotherapeutic approaches, and prescription of inadequate doses of antidepressant medication for inadequate durations. Mental health care systems create barriers to receiving optimal treatment. Strategies to narrow the gap include enhancing the role of patients and families as participants in care and advocates; developing performance standards for behavioral health care systems, including incentives for positive identification, assessment, and treatment of depression; enhancing educational programs for providers and the public; enhancing collaboration among provider subtypes (eg, primary care providers and mental health professionals); and conducting research on development and testing of new treatments for depression.

Antidepressive Agents↗

PubMedDate not supplied

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

OBJECTIVE: A consensus conference on the diagnosis and treatment of Alzheimer disease (AD) and related disorders was organized by the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society on January 4 and 5, 1997. The target audience was primary care physicians, and the following questions were addressed: (1) How prevalent is AD and what are its risk factors? What is its impact on society? (2) What are the different forms of dementia and how can they be recognized? (3) What constitutes safe and effective treatment for AD? What are the indications and contraindications for specific treatments? (4) What management strategies are available to the primary care practitioner? (5) What are the available medical specialty and community resources? (6) What are the important policy issues and how can policymakers improve access to care for dementia patients? (7) What are the most promising questions for future research? PARTICIPANTS: Consensus panel members and expert presenters were drawn from psychiatry, neurology, geriatrics, primary care, psychology, nursing, social work, occupational therapy, epidemiology, and public health and policy. EVIDENCE: The expert presenters summarized data from the world scientific literature on the questions posed to the panel. CONSENSUS PROCESS: The panelists listened to the experts' presentations, reviewed their background papers, and then provided responses to the questions based on these materials. The panel chairs prepared the initial drafts of the consensus statement, and these drafts were read by all panelists and edited until consensus was reached. CONCLUSIONS: Alzheimer disease is the most common disorder causing cognitive decline in old age and exacts a substantial cost on society. Although the diagnosis of AD is often missed or delayed, it is primarily one of inclusion, not exclusion, and usually can be made using standardized clinical criteria. Most cases can be diagnosed and managed in primary care settings, yet some patients with atypical presentations, severe impairment, or complex comorbidity benefit from specialist referral. Alzheimer disease is progressive and irreversible, but pharmacologic therapies for cognitive impairment and nonpharmacologic and pharmacologic treatments for the behavioral problems associated with dementia can enhance quality of life. Psychotherapeutic intervention with family members is often indicated, as nearly half of all caregivers become depressed. Health care delivery to these patients is fragmented and inadequate, and changes in disease management models are adding stresses to the system. New approaches are needed to ensure patients' access to essential resources, and future research should aim to improve diagnostic and therapeutic effectiveness.

Alzheimer Disease↗

PubMed1997

[Mood disorders in daily practice; the North American consensus statement on the undertreatment of depression].

The American National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression may have consequences for the treatment of patients in the Netherlands. It is concluded that Dutch clinicians, also, can be expected to play a more active role in cases of mood disorders than formerly. A comparison of the definitions of depressive disorder in the available classification system results in the recommendation to be strict about the distinction between severe and moderate depressive disorders on the one hand and subthreshold or mild conditions on the other. It is expected that this will limit the anticipated shift towards a more general willingness to use pharmacotherapy for mood disorders in patients in whom this can be expected to be efficacious.

Antidepressive Agents↗

PubMed1998

Consensus statement on cereals, fibre and colorectal and breast cancers. Proceedings of the European Cancer Prevention consensus meeting. Santa Margheritia, Italy, 2-5 October 1997.

The consensus meeting on 'Cereals, fibre and colorectal and breast cancers' was attended by 17 dietary and cancer experts; a further eight who could not attend the discussions were deemed corresponding participants and gave their views by post and telephone. The agreed consensus statement is given here.

Breast Neoplasms↗

PubMed1998

Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists.

The Cancer Committee of the College of American Pathologists has prepared an update of the consensus statement on premalignant breast lesions and breast cancer risk that was originally published in the Archives of Pathology & Laboratory Medicine in 1986. The objective of this publication is to better define the relative breast cancer risk associated with specific histologic abnormalities by incorporating data derived from recent case-control studies. Explanatory notes are used to document and explain specific risk classifications. In addition to refining the degree of risk associated with individual lesions, such as fibroadenoma and atypical hyperplasia, this update includes a discussion of age-specific breast cancer risk and provides examples that can be used when counseling patients.

Age Factors↗

PubMed2001

Problems with proper completion and accuracy of the cause-of-death statement.

BACKGROUND: Mortality statistics are largely based on death certificates, so it is important that the data on the death certificate is accurate. At our institution, clinicians complete cause-of-death statements (CODs) prior to autopsy. Since May 1995, separate CODs have been included in autopsy face sheets. METHODS: Clinical and autopsy-based CODs filled out separately on 494 cases between June 1995 and February 1997 were compared for proper reporting and accuracy using the published guidelines and definitions of immediate, intermediate, and underlying causes of death put forth by the College of American Pathologists and the National Center for Health Statistics. RESULTS: Of the 494 death certificates, 204 (41%) contained improperly completed CODs. Of these, 49 (24%) contained major discrepancies between clinicians' and pathologists' CODs. Of the 494 death certificates, 290 (59%) had properly completed CODs. Of the 290 properly completed CODs, 141 (49%) contained disagreements: 73 (52%) on underlying CODs; 44 (31%) on immediate CODs; and 47 (33%) on other significant conditions (part II). CONCLUSIONS: The reliability and accuracy of CODs remain a significant problem. Despite its limitations, the autopsy remains the best standard against which to judge premortem diagnoses. The CODs of the death certificate may be improved if death certificates are completed in conjunction with the postmortem examination and amended when the autopsy findings show a discrepancy.

Autopsy↗

PubMed1992

Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement.

Several antibiotics have been marketed for therapeutic use in intra-abdominal infection. Often, these agents do not provide a sufficient spectrum activity against both facultative and obligate anaerobic gram-negative organisms, or have certain toxic effects that would not otherwise support their use. Guidelines have been developed for selection of antibiotic therapy for intra-abdominal infections and are presented as a statement of the Surgical Infection Society endorsed by the Executive Council. These guidelines are restricted to infections derived from the gastrointestinal tract and deal with those microorganisms commonly seen in such infections. The recommendations are based on in vitro activity against enteric bacteria, experience in animal models, and documented efficacy in clinical trials. Other concerns regarding pharmacokinetics, mechanisms of action, microbial resistance, and safety were also used in the formation of these guidelines. For community-acquired infections of mild to moderate severity, single-agent therapy with cefoxitin, cefotetan, or cefmetazole or ticarcillin-clavulanic acid is recommended. For more severe infections, single-agent therapy with carbapenems (imipenem/cilastatin) or combination therapy with either a third-generation cephalosporin, a monobactam (aztreonam), or an aminoglycoside plus clindamycin or metronidazole is recommended. Regimens with little or no activity against facultative gram-negative rods or anaerobic gram-negative rods are not considered acceptable.

Abdomen↗

PubMed2006

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

The CONSORT (Consolidated Standards of Reporting Trials) Statement, including a checklist and a flow diagram, was developed to help authors improve their reporting of randomized controlled trials. Its primary focus was on individually randomized trials with 2 parallel groups that assess the possible superiority of one treatment compared with another but is now being extended to other trial designs. Noninferiority and equivalence trials have methodological features that differ from superiority trials and present particular difficulties in design, conduct, analysis, and interpretation. Although the rationale for such trials occurs frequently, those designed and described specifically as noninferiority or equivalence trials appear less commonly in the medical literature. The quality of reporting of those that are published is often inadequate. In this article, we present an adapted CONSORT checklist for reporting noninferiority and equivalence trials and provide illustrative examples and explanations for those items amended from the original CONSORT checklist. The intent is to improve reporting of noninferiority and equivalence trials, enabling readers to assess the validity of their results and conclusions.

Publishing↗

PubMed2001

Extending the CONSORT statement to cluster randomized trials: for discussion.

The need for clear reporting of randomized controlled trials has been emphasized recently. The CONSORT Statement has made evidence-based suggestions for a checklist and a patient flow diagram. Adapting this for cluster randomized controlled trials presents particular challenges. Simple changes in the checklist and diagram for the completely randomized two level cluster randomized trials are suggested for discussion. An example taken from an unpublished trial demonstrates that these changes are less simple to implement, although extensions to electronic publications may be helpful. These suggestions should be formally evaluated. Further work is required to consider the cases of more levels and of stratified or pair-matched cluster randomized trials.

Cluster Analysis↗

PubMed2003

Commitment to change statements can predict actual change in practice.

INTRODUCTION: Statements of commitment to change are advocated both to promote and to assess continuing education interventions. However, most studies of commitment to change have used self-reported outcomes, and self-reports may significantly overestimate actual performance. As part of an educational randomized controlled trial, this study documented changes that family physicians committed to make in their prescribing and then used third-party data to examine actual changes. METHOD: Following participation in a continuing medical education program using interactive small groups, physicians were asked to identify changes that they planned to make in their practices. For prescribing changes related to four conditions, data from a provincial pharmacy registry were analyzed for 6-month periods before and after the educational intervention. RESULTS: A total of 207 physicians participated in the project, which involved monthly meetings of 30 peer learning groups. Ninety-nine physicians received experimental case-based educational modules +/- personal prescribing feedback, and 91 of these indicated that they planned to make at least one change in practice. Of the 209 intended changes, 71% were directly related to the prescribing messages in the materials. DISCUSSION: In three of four indicator conditions, physicians who expressed a commitment to change were significantly more likely to change their actual prescribing for the target medications in the following 6 months. The percentage of physicians who did change their prescribing varied significantly by condition. Further study of the process of translating commitment to change into real practice change is needed.

Attitude of Health Personnel↗

PubMed2006

The case against no-suicide contracts: the commitment to treatment statement as a practice alternative.

This article reviews the literature on the use of "no-suicide contracts" in clinical practice, including conceptual discussions, patient and clinician surveys, and a few empirical studies on clinical utility. Our primary conclusion is that no-suicide contracts suffer from a broad range of conceptual, practical, and empirical problems. Most significantly, they have no empirical support for their effectiveness in the clinical environment. The authors provide and illustrate the commitment to treatment statement as a practice alternative to the no-suicide contract.

Contracts↗

PubMed2000

Statement 'the use of patient-related information in medical research and the health system'.

Patient-related information is regularly recorded in surgeries and hospitals. The health system produces such 'person-related health data' in astronomical numbers. Millions of data are entered into and processed by the computing systems of many different institutions. They are used for the treatment of patients and the calculation of health fund benefits and in addition, given a systematic and methodologically controlled evaluation, they can be used to detect health risks, assess more accurately the consequences of risks and diseases, compare the benefits of different therapies, or rank health care goals. Since health data are person-related their recording and use are subject to the consent of the person in question. Besides, the information which the patient provides or which is established regarding the patient, is protected by the confidentiality to which all doctors are held; if it is passed on to calculate health benefits it is protected by the confidentiality of social security data. Beyond this moral and legal protection the use of person-related health data requires explicit legal justification. In view of the multitude of uses which the current level of data processing affords, no legal regulation can determine every possible instance comprehensively and definitively in advance. Rather, a moral and legal evaluation of each instance is needed. It is not without reason that the data protection laws contain more or less comprehensive general clauses and indeterminate legal concepts. The Central Ethics Commission at the German Medical Association (Bundesärztekammer) has put out a statement on these matters. It asks the legislature to improve the protection for individuals with respect to the use of patient data for research in medicine and the health system in accordance with EU-Directive (No. 95/46/EG of 24 October 1995). Moral and legal problems occur mainly when, for objective reasons, the consent of the persons in question cannot be obtained, yet the further use of the data is important in order to improve the care of the patients. The Central Ethics Commission suggests the establishment of independent bodies along the lines of ethics commissions to undertake the necessary judgments between individual protection and the importance of the purpose for which the data are to be used. It further argues that if used in medical research or the health system the data are given the same degree of protection as they were by the doctor to whom they were first confided.

Confidentiality↗